FDA Panel Recommends Approval For InterMune's Esbriet
A Food and Drug Administration advisory panel recommended approval for InterMune Inc.'s (Nasdaq: ITMN) fatal lung disease treatment Esbriet sending the stock price soaring $14.88 to $38.18.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.